baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC BON.CAP.CERT. 12/24 SNW/ DE000HD61DZ7 /

2024-09-06 9:46:30 PM	Chg.+0.180	Bid9:59:10 PM	Ask9:59:10 PM	Underlying	Strike price	Expiration date	Option type
152.600EUR	+0.12%	152.380 Bid Size: 400	152.530 Ask Size: 400	SANOFI SA INHABER ...	- -	2024-12-31	Call

GlobeNewswire 09-02 Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to ...

GlobeNewswire 08-26 Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...

GlobeNewswire 08-14 Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

GlobeNewswire 08-13 Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 08-12 MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter ...

GlobeNewswire 08-12 MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi

GlobeNewswire 08-08 Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free sur...

GlobeNewswire 08-06 Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D ...

GlobeNewswire 08-05 Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024

GlobeNewswire 08-02 Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

GlobeNewswire 08-01 Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire 08-01 Regeneron Reports Second Quarter 2024 Financial and Operating Results

GlobeNewswire 07-31 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2...

GlobeNewswire 07-25 Press Release: Online availability of Sanofi’s half-year financial report for 2024

TeleTrader 07-25 Europe lower premarket as earnings pour in

TeleTrader 07-25 Sanofi net sales up 7.8% to €10.7B in Q2

GlobeNewswire 07-25 Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded

GlobeNewswire 07-24 US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold...

GlobeNewswire 07-18 Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, Accord...

GlobeNewswire 07-17 Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transfor...

GlobeNewswire 07-12 FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows ...

GlobeNewswire 07-11 Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Upd...

GlobeNewswire 07-08 Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review ...

GlobeNewswire 07-03 Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...

GlobeNewswire 07-03 Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD

UC BON.CAP.CERT. 12/24 SNW/ DE000HD61DZ7 /

If you wish to receive reply to your feedback, please provide your email address.